Next Generation Development of Genome and Cellular Therapy Program

【Research Keyword】
Cancer immunotherapy, Adoptive genome-edited T-cell therapy, Clinically usable high-fidelity artificial nuclease, Targeted T-cell genome editing, Comprehensive single-cell-based immune repertoire analyses

【Recent highlights】
In Oct. 2019, we have launched a new research program named “Next Generation Development of Genome and Cellular Therapy Program”in partnership between Department of Hematology and Oncology in Research Institute for Radiation Biology and Medicine, Hiroshima University and Repertoire Genesis incorporated.
Our mission is to promote research on cancer immunity, and to develop novel cellular immunotherapy for cancers or other disorders.
We strongly believe that the collaboration between Repertoire Genesis incorporated, a leading company in the field of immunological analyses and Hiroshima University forcefully advances research on understandings of cancer immunity and promotes the development of innovative cellular immunotherapies for cancers and other disorders.

【Department of Next Generation Development of Genome and Cellular Therapy Program】

Name	Title
Takero Shindo	Professor

【Research】
Our research group started in Oct. 2019 with collaboration between Department of Hematology and Oncology in Research Institute for Radiation Biology and Medicine, Hiroshima University and Repertoire Genesis incorporated (Ibaraki, Osaka, Japan), to develop novel cellular immunotherapies against cancers and other disorders.
Now, cellular immunotherapy using peripheral T cells of patients such as chimeric antigen receptor-T cells (CAR-T cells) therapy or T cells transduced with cancer-specific T cell receptors (TCR-T cell) therapy have been started to be used in clinical settings, and have caught much attention due to their promising clinical data. However, in these therapies, there are multiple issues to be cleared or overcome at this current moment, especially in issues on efficacy, safety, cost-effectiveness, and others. By synergizing cutting-edge-technology of Repertoire Genesis inc. in immunology field and abundant research seeds of Hiroshima University, we enthusiastically tackle these issues, and we hope that we shortly bring innovative immunotherapies to as many patients as possible from our country to all over the world.

Our research is focusing on

To development new cellular immunotherapies against cancers.
To find out novel cancer-specific antigens which are targetable in immunotherapy.
To analyze single-cell-based antigen-specific TCR/BCR clonotypes using next generation sequencers.
To develop gene-modified cellular immunotherapy for non-neoplastic disorders.
To make cellular immunotherapy more cost-effective and more convenient for many patients.

Site Policy Privacy Policy